Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase kappa (POLK) is a human Y-family DNA polymerase involved in translesion synthesis, a DNA damage tolerance process that allows replication to proceed past certain DNA lesions that block replicative polymerases[3][5]. POLK can bypass various DNA lesions, including bulky adducts and oxidative damage, but does so with lower fidelity, sometimes introducing mutations. It plays an important role in maintaining genome stability under conditions of DNA damage but, due to its error-prone nature, unchecked activity may contribute to mutagenesis and cancer development[2][5]. The protein contains a distinct N-terminal N-clasp domain critical for its catalytic mechanism and DNA lesion bypass activity[1].
Enables translesion DNA synthesis, allowing the DNA replication machinery to bypass DNA lesions by incorporating nucleotides opposite damaged bases, with relatively low fidelity[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase kappa (POLK).